- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05211206
IV Fluids and Post-ERCP Pancreatitis
Association Between Peri-procedural Intravenous Hydration and Post- Endoscopic Retrograde Cholangiopancreatography Pancreatitis
Study Overview
Detailed Description
Background and Rationale
While very effective, endoscopic retrograde cholangiopancreatography (ERCP) is widely known to have the highest adverse event (AE) profile among all commonly performed endoscopic procedures, with a collective AE rate of >10%. Common AEs include post-ERCP pancreatitis (PEP), bleeding, cholangitis, cholecystitis, perforation, and cardiopulmonary events. PEP is the most common, with estimated rates of 5-10%. It is noteworthy that both the incidence of PEP and its associated mortality are rising.
It is of critical priority to patients, practitioners, and health administrators to investigate factors associated with all AEs and unplanned healthcare encounters (UHEs) following ERCP, especially given that most ERCPs are performed on an outpatient basis. The per-admission costs of post-ERCP UHEs are substantial, exceeding $10,000 and $70,000 for pancreatitis and cholangitis, respectively. PEP alone accounts for an estimated $200+ million in annual healthcare spending in the United States. Thus, researchers must prioritize the study of ERCP outcomes, striving to both identify and modify factors leading to AEs and UHEs.
Peri-procedural fluid management and its relationship with ERCP outcomes also remains incompletely understood. Aggressive intravenous hydration (AH) has been shown to reduce the risk of PEP compared with standard peri-procedural hydration regimens. However, all AH regimens studied to date involve continuous hydration for 8-24 hours, which is impractical and thus non-generalizable to almost all North American outpatient ERCPs practices. To date, no studies have prospectively assessed short-term (60-90 minute) aggressive hydration regimens that are feasible for outpatients undergoing ERCP and subsequent discharge. Furthermore, little is known with regard to fluid type, volume, and timing with respect to ERCP.
Research Question and Objectives
In this study, we will aim to assess whether the amount of peri-procedural intravenous fluid administered around the time of ERCP is associated with the risk of PEP (the primary outcome).
- Methods
Design: This is a retrospective cohort study where all data used to answer the proposed research question will be obtained from research data previously collected under REB18-0410. REB18-0410 (CReATE) is a multicenter prospective cohort study that recruits patients undergoing ERCP during which various relevant clinical and patient demographic data have been collected. The objective of REB18-0410 is to determine the clinical effectiveness and adverse event profile of ERCP.
The exposure variable for this study will be a the total peri-procedural IV fluid volume administered, measured and reported as a continuous variable. In addition to these variables, other parameters we will assess include: the presence and timing of pharmacologic PEP prophylaxis, extent and timing of trainee involvement, the number and timing of common bile duct (CBD) cannulation attempts, the depth, timing, trajectory and number of PD cannulation(s), the presence and extent of PD opacification, the size(s) of sphincterotomy and/or sphincteroplasty, intra-procedural pathology, and the composition, caliber and length of any PD or CBD stent(s).
Outcomes: The primary outcome will be PEP, using established definitions. Secondary outcomes (defined a priori) will include PEP severity, overall and specific AEs (bleeding, cholangitis, cardio-pulmonary events), cannulation time and success rate, as well as overall procedure time and success rate.
Sample Size and Power: Using a cutoff of a total peri-procedural IV fluid volume of ≥ 2 L (versus < 1 L), a minimum of 1,530 patients are anticipated to meet the exposure definition, with an anticipated 12,750 patients that will meet the control definition. We will be able to demonstrate increases in PEP risk from 5.0% to 6.8% (a relative increase of 36%) with 82.3% power or from 5.0% to 7.0% (a relative increase of 40%) with 88.6% power.
Statistical Analysis: Variables will be compared using Student's t-test for measured variables and chi-squared test for categorical variables. P values < 0.05 will be considered significant. We will use multivariable logistic regression to assess associations between risk factors and having PEP versus not having PEP. Clinically relevant subgroup analyses will also be performed by relevant patient-, endoscopist-, and procedure-related characteristics. Odds ratios per outcome will be reported with 95% CIs.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Nauzer Forbes, MD MSc
- Phone Number: 403-592-5089
- Email: nauzer.forbes@ucalgary.ca
Study Locations
-
-
Alberta
-
Calgary, Alberta, Canada
- Recruiting
- Peter Lougheed Hospital
-
Contact:
- Nauzer Forbes, MD MSc
- Phone Number: 403-592-5089
- Email: nauzer.forbes@ucalgary.ca
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Subject referred for ERCP, regardless of indication;
- Subject age 18 years or older;
- Subject able to give informed consent to involvement be included.
Exclusion Criteria:
- Subject has a standard contraindication to ERCP;
- Subject or surrogate unable or unwilling to provide informed consent;
- Subject age < 18 years.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Aggressive hydration
Patients with greater than or equal to 2 L of intravenous crystalloid fluids administered within the immediate pre-, peri- and post-procedural period
|
Amount of intravenous fluids delivered
|
Conservative hydration
Patients with less than 1 L of intravenous crystalloid fluids administered within the immediate pre-, peri- and post-procedural period
|
Amount of intravenous fluids delivered
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
post-ERCP pancreatitis
Time Frame: 30 days
|
Number of participants with any 2 of: (1) epigastric abdominal pain, (2) serum amylase/lipase >3x the upper limit of normal, (3) imaging findings consistent with acute pancreatitis
|
30 days
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Nauzer Forbes, MD MSc, University of Calgary
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- REB21-1885
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on ERCP
-
Istituto Clinico HumanitasRecruiting
-
University of CalgaryMcGill University; University of Ottawa; Queen's University; Halton Health (Oakville) and other collaboratorsCompleted
-
The University of Texas Health Science Center,...Wake Forest University Health Sciences; Instituto Ecuatoriano de Enfermedades...Unknown
-
Changhai HospitalUnknown
-
Air Force Military Medical University, ChinaDepartment of Endoscopy, Eastern Hepatobiliary Hospital, Second Military... and other collaboratorsRecruiting
-
Menoufia UniversityCompletedERCP, Difficult CBD CannulationEgypt
-
Postgraduate Institute of Medical Education and...AMRI Hospital, Salt Lake, Kolkata, IndiaCompleted
-
Assiut UniversityCompleted
-
Hospital Clinic of BarcelonaUnknownPatient Population Submitted to ERCPSpain
Clinical Trials on IV fluids
-
Stanford UniversityCompleted
-
Bnai Zion Medical CenterCompletedViral BronchiolitisIsrael
-
Samsung Medical CenterCompleted
-
Austin HealthCompletedCardiac SurgeryAustralia
-
The Hospital for Sick ChildrenCompleted
-
Federal University of Minas GeraisCompletedThirst | Postoperative Nausea | Postoperative Vomiting | Hunger | Fluid Electrolyte Disorders | Renal Function Abnormal
-
Massachusetts General HospitalMount Auburn Hospital; Pro EMSWithdrawn
-
University of CalgaryMedical University of South Carolina; University of Colorado, Denver; The Hospital... and other collaboratorsRecruitingHemolytic-Uremic Syndrome | Shiga Toxin-Producing Escherichia Coli (E. Coli) InfectionUnited States, Canada
-
Mt. Sinai Medical Center, MiamiFlorida Heart Research InstituteCompleted
-
University of Colorado, DenverCompletedPain, Postoperative | Femoro Acetabular ImpingementUnited States